The U.S. argon-helium ultra-cold knife minimally invasive targeted tumor treatment technology is the world’s only high-tech medical system with multiple efficacies such as -150 degrees ultra-low temperature freezing, interventional thermotherapy, 200 degrees great temperature difference and immune enhancement, which is superior to purely hot or cold technology. Due to its clinical efficacy of less trauma, precise control and targeted destruction of tumor, it makes most tumor patients who have lost the chance of radical resection by conventional surgery regain the opportunity of minimally invasive surgical treatment. It can completely destroy the targeted tumor tissues, and most of the 2-10cm tumors can be treated once to achieve the purpose of local ablation, which can rapidly and maximally reduce the tumor load, rapidly reduce pain and improve the quality of life of patients, effectively prolonging life and even cure. In the past ten years, a large amount of relevant clinical data has been published, confirming the safety and effectiveness of the U.S. argon-helium supercooled knife cryoablation for the treatment of liver, lung, brain, prostate, breast, kidney, pancreas and various solid tumors. It is the high-tech tumor treatment after radio frequency ablation technology, microwave, laser, ultrasonic aggregation knife, gamma knife, X-knife, neutron knife. It has significant advantages in the treatment of lung cancer, liver cancer, breast cancer, kidney tumor and other solid tumors. It represents the most advanced level of tumor treatment in the world. Liu Yanshui, Minimally Invasive Tumor Department, Qianfoshan Hospital, Shandong Province, China In 1999, China’s State Administration of Medicine approved the entry of argon-helium supercooled knife into China, and China’s famous academician Wu Mengchao, academician Tang Zhaoyou, academician Hao Xishan, and other domestic specialists have successively applied this technology to more than 20,000 cases of mid- to late-stage liver, lung, breast, pancreatic, brain tumors, prostate, and renal tumors, and have achieved remarkable results. The technology has achieved remarkable results. Ar-He knife is the only minimally invasive targeted therapy system in the world that combines multiple therapeutic effects such as ultra-low temperature freezing, interventional thermotherapy and immune enhancement. Equipped with 4 or 8 individually controllable cutterheads, the inner hollow of the cutterbar can circulate high-pressure normal temperature argon (refrigerant) and high-pressure normal temperature helium (thermal medium), and temperature couples are directly installed in the tip of the cutter, which can continuously detect the temperature of the tip of the cutter. During treatment, the argon helium knife is inserted into the tumor tissue under the direct vision of CT, ultrasound, X-ray, laparoscopy, thoracoscopy, or under the direct vision of surgery, and the helium is turned on by computer control, the diseased tissue at the tip of the knife can be cooled down to -140℃-175℃ in 60 seconds, and the ablation target area of 2-9cm is formed, and then the helium is turned on, and the helium can expand rapidly, so that the frozen tissue is frozen. Rapid expansion of helium at the tip of the knife, so that the frozen lesion tissue quickly warmed to +45 ℃. This rapid reversal of heat and cold can completely destroy the diseased tissue. The use of argon helium knife: argon helium knife is developed by the U.S. Endocare company, in 1998 through the U.S. FDA’s strict approval, began a wide range of applications in the clinical treatment of solid tumors, and was approved by the U.S. FDA and the Medical Finance Bureau to enter the public health care system, the United States currently has more than 360 hospitals equipped with argon helium knife equipment, our country since the introduction in 1999 the first argon helium knife Since the introduction of the first argon helium knife in China in 1999, nearly 40 hospitals have established argon helium knife treatment centers, and more than 20,000 cases of various types of solid tumors have been treated. Indications: (1) Malignant solid tumors: liver cancer, lung cancer, breast cancer, pancreatic cancer, brain tumor, thyroid tumor, prostate cancer, kidney and adrenal tumor, abdominal and pelvic tumor, bone tumor, soft tissue tumor, head and neck and skin tumor, metastatic gastrointestinal tumor and other solid tumors. (2) Benign tumors and benign hyperplastic lesions: prostate hyperplasia, benign breast tumors, hemangiomas, uterine fibroids, cysts and so on. Clinical advantages: (1) Simple operation, wide range of indications, can be practiced alone or combined with chemotherapy, radiotherapy, traditional Chinese medicine or surgical treatment. (2) No toxicity to the patient, small damage, few complications, fast recovery, and remarkable local ablation effect. Clinical efficacy and evaluation: The clinical efficacy of argon helium knife in the treatment of solid tumors has been recognized by many patients, medical experts and medical institutions, with 89-100% ablation rate in local target area. After 6 years of multi-center clinical practice in different countries, experts in China, the United States and Japan suggest that; Ar-He knife minimally invasive treatment of tumors should now be included in the first choice of inoperable intermediate and advanced tumors, and some experts believe that Ar-He knife minimally invasive treatment is also suitable for patients with solid tumors who are unwilling to undergo surgical resection in early stage.